ClearFlow

Executive Summary

ClearFlow, Inc. is a private medical device company based in Anaheim, California, dedicated to improving outcomes for cardiac surgery patients. Founded in 2005, the company has developed two key products: PleuraFlow Active Clearance Technology, which actively maintains chest tube patency in the ICU to prevent Retained Blood Syndrome, and the ClearFix system, a rigid sternal fixation solution for post-sternotomy stabilization. These technologies address common complications that extend hospital stays and increase costs, offering a value proposition for both patients and healthcare providers. Though the company is early-stage with limited public financial data, its focus on a clear clinical need in a large market positions it for potential growth. The PleuraFlow system, in particular, has the potential to become standard-of-care in cardiac surgery ICUs if adoption scales.

Upcoming Catalysts (preview)

• Q3 2026Publication of additional clinical outcomes data for PleuraFlow demonstrating reduced ICU stays or complications70% success
• Q4 2026FDA clearance or CE marking expansion for a next-generation PleuraFlow device or ClearFix variant50% success
• 2027Partnership with a major hospital network or cardiac surgery group to standardize use of PleuraFlow40% success